Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes: Academics’, Clinicians’, Industry’s, Regulators’, and Payers’ Perspectives.

Link to article at PubMed

Related Articles

Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes: Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.

Heart Fail Clin. 2013 Jul;9(3):285-90

Authors: Gheorghiade M, Shah AN, Vaduganathan M, Butler J, Bonow RO, Rosano GM, Taylor S, Kupfer S, Misselwitz F, Sharma A, Fonarow GC

Abstract
Hospitalized heart failure (HHF) is associated with unacceptably high postdischarge mortality and rehospitalization rates. This heterogeneous group of patients, however, is still treated with standard, homogenous therapies that are not preventing their rapid deterioration. The costs associated with HHF have added demands from society, government, and payers to improve outcomes. With coordinated and committed efforts in the development of new therapies, improvements may be seen in outcomes for patients with HHF. This article summarizes concepts in developing therapies for HHF discussed during a multidisciplinary panel at the Heart Failure Society of America's Annual Scientific Meeting, September 2012.

PMID: 23809415 [PubMed - in process]

Leave a Reply

Your email address will not be published.